💨 Abstract

PTC Therapeutics Inc. (PTCT) reported a Q2 loss of $64.8 million, or 83 cents per share, beating Wall Street expectations of a $1.07 per share loss. Revenue for the quarter was $178.9 million, surpassing the forecasted $170.7 million. The company forecasts full-year revenue between $650 million and $800 million.

Courtesy: WTOP Staff